NRC FORM 591M PA (11-2003)	ART 1		U.S. 1	NUCLEAR REGULATO	RY COMMISSION			
10 CFR 2.201	SAFETY INSPECTION	REPORT	T AND COMPLIANCE IN	SPECTION S	7			
1. LICENSEE/LOCATIO		2. NRC/REGIONAL OFFICE						
Mayo Clinic Rochester			Region III					
Mayo Clinic Rochester Mayo Clinic Rochester Campus			Region III. 2443 Warrenville Rd. Lisle, IL 60432					
Rochester, MN			Lisle, IL 60432					
REPORT NUMBER(S	1) 2005-001							
		4. LICENSE N						
030021	1002195 22-		005/9-03	10/18-21/05				
Regulatory Commission procedures and representations	n examination of the activities conducted on (NRC) rules and regulations and the sentative records, interviews with personal transfer and the conductions are sentenced.	e conditions o onnel, and ob	f your license. The inspection consist servations by the inspector. The inspector.	sted of selective examir	nations of			
1. Based on	1. Based on the inspection findings, no violations were identified.							
2. Previous v	Previous violation(s) closed.							
3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.								
	non-cited violation(s) were discussed involving the following requirement(s):							
			•					
4. During this	s inspection, certain of your activities, a s form is a NOTICE OF VIOLATION, w	ıs described b	pelow and/or attached, were in violati	on of NRC requirement	ts and are being			
		men may be s	subject to posting in accordance with					
(Violations	(Violations and Corrective Actions)							
			•					
	Sta	tement of (	Corrective Actions					
I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.								
TITLE	PRINTED NAME		SIGNATURE		DATE			
LICENSEE								
NRC INSPECTOR	Robert G. Gattone, Jr	Geoffre Warre	Robert D. Hattone J	2/AlaWan	10/21/05			
NRC FORM 591M PART 1 (1	11-2003)				ON RECYCLED PAPER			

NRC FORM 591M PART	3		U.S. NUCLEAR REGULATORY COMMISSION					
Docket File Information  SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATION IN	SPECTED:	2. NRC/REGIONAL OFFICE						
Mayo Clinic Roch	ester	DECION III						
REPORT NUMBER(S) 2	005-001	REGION III						
3. DOCKET NUMBER(S)		4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION					
03002195		22-00519-03	10/18-21/05					
6. INSPECTION PROCEDUR	ES USED	7. INSPECTION FOCUS AREAS						
87134		03.01, 03.02, 03.03, 03.04, 03.05, 03.06 and 03.07						
SUPPLEMENTAL INSPECTION INFORMATION								
1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT 4. TELEPHONE NUMBER						
02110	1	Richard Vetter, Ph.D., RSO 507-284-4408						
✓ Main Office Inspection  ☐ Field Office Inspection		Next Inspection Date: 10/2	1/2006					
Temporary Job Site Inspection								

## PROGRAM SCOPE

The licensee conducted licensed activities at its facilities located at the Mayo Clinic Rochester campus, Rochester, Minnesota. The licensee also conducted mobile nuclear medicine at temporary job sites of medical care facilities anywhere in the United States where the NRC maintained jurisdiction for regulating the use of licensed material. Licensed activities included high dose rate (HDR) brachytherapy; activities listed in 10 CFR 35.400 including Cs-137 gynecological treatments, Ir-192 seeds encased in ribbon, I-125 seeds for prostate treatments, and I-125 seeds for eye therapy; mobile nuclear medicine limited to activities listed in 10 CFR 35.200; full spectrum nuclear medicine at Methodist Hospital; cardiac nuclear medicine at the Gonda Building and St. Mary's Cardiac Clinic; primarily diagnostic nuclear medicine at St. Mary's Hospital; research and development primarily involving in-vitro protein labeling with several radionuclides (e.g., P-32, I-125, H-3, S-35, P-33); I-125 iodinations; animal studies; five irradiators for irradiation of blood, tissues, and animal research; and daily incineration of licensed material.

## PERFORMANCE OBSERVATIONS

The inspectors observed the administration of licensed material to a human research subject; use of a blood irradiator and a research irradiator; use of the incinerator; incinerator personnel demonstrate a survey of the ash bin; selected staff perform survey meter operability checks; selected staff demonstrate the preparation of a shipping paper for a shipment between licensee facilities; a demonstration of a package receipt survey; licensee staff perform calibration checks of several survey meters; a nuclear medicine technologist demonstrate response to a radioactive spill; selected staff demonstrate how diagnostic and therapeutic radiopharmaceuticals were administered to patients; daily spot checks of an HDR remote afterloader; selected staff demonstrate emergency response to an HDR event; an authorized medical physicist conduct a physics check of an HDR treatment; authorized staff administer an HDR treatment; selected staff demonstrate how the HDR unit was moved between authorized facilities; selected health physics staff conduct periodic audits of selected laboratories; and selected staff conduct removable contamination and ambient exposure rate surveys.